RxData

RxData's latest blog post: "September 2023 AIFA decisions under the Spotlight" rxdata.net/blog/september-20… #AIFA #MarketAccess

RxData's latest blog post: "Overheard at ISPOR: IRA Drug Price Negotiations" rxdata.net/blog/overheard-is… #ISPOR

RxData is aware that certain individuals are impersonating RxData recruiters. Note that we will not send unsolicited invitations to apply for any position, and will not require payment, credit card/bank info or delivery of personal information in connection with any application.

This week in Market Access!! VIDEO BELOW youtu.be/psPwRB4JEj8 #marketaccess

This week in Market Access!! VIDEO BELOW youtu.be/u0FYQfWnKfM #PharmaMarketAccess

Another week goes by and PharmaWeekly sums it up for you… Pharma Market Access at your fingertips – the RxData promise. See this week’s video below! youtu.be/KZfGoaYoGzo #PharmaMarketAccess

This past week in Pharma Market Access… youtu.be/pK4S6R-u814 #MarketAccess #Pharma #PharmaAccess

As customary, find out what happened this week in Pharma Market Access. Happy Friday! youtu.be/Tw2L7qzRGGw #Pharma #MarketAccess

PharmaWEEKLY wishes you a wonderful Friday! As always, this weekly video (<1 minute) showcases some of the most important market access decisions of the past week! youtube.com/watch?v=sCK4K0hf… #MarketAccess #Pharma

PharmaWeekly brings you this week's important Market Access events... Have a wonderful Friday! youtu.be/agae6XQIJ5U #HappyFriday #Pharma #PharmaMarketAccess

PharmaWEEKLY - Your Weekly Digest of Market Access Events. August 17 is out! Happy Friday! youtu.be/UlawPRFHhao #MarketAccess #Pharma #FDA #EMA #HealthCanada #PharmaWEEKLY #GlobalMarketAccess #DrugPricing #DrugReimbursement #DrugApproval #RxData

Friday's PharmaWEEKLY at your service youtube.com/watch?v=-QW6UVpj… #MarketAccess #Pharma #FDA #EMA #HealthCanada #PharmaWEEKLY #GlobalMarketAccess #DrugPricing #DrugReimbursement #DrugApproval #RxData

What happened in Market Access? youtube.com/watch?v=U4Yxj-yP… #MarketAccess #Pharma #FDA #EMA #HealthCanada #PharmaWEEKLY #GlobalMarketAccess #DrugPricing #DrugReimbursement #DrugApproval #RxData

Another week, another PharmaWEEKLY! bit.ly/pharmaweeklyjul727 What happened in Market Access this week? #MarketAccess #Pharma #FDA #PharmaWEEKLY #GlobalMarketAccess #EMA #DrugPricing #DrugReimbursement #DrugApproval #HealthCanada #RxData

Happy Friday! This week's Market Access Events now available in our PharmaWEEKLY video bit.ly/pharmaweeklyjuly20 #MarketAccess #Pharma #FDA #PharmaWEEKLY #GlobalMarketAccess #EMA #DrugPricing #DrugReimbursement #DrugApproval #HealthCanada #RxData

This week in pharma Market Access (July 13) - bit.ly/pharmaweeklyjuly13 … #pharmaweekly #marketaccess #pharma #fda #ema #pharmapricing #pharmareimbursement #rxdata

This week in #marketaccess - bit.ly/pharmaweeklyjuly6 #pharmaweekly #pharma #fda #ema #pharmapricing #pharmareimbursement

Did you know that 33% of Part D lives have diverging Praluent / Repatha formulary placement? RxData can tell you more about these coverage differences - sign up now. #MarketAccess bit.ly/2p8xxe8

pCODR conditionally recommends the reimbursement of VENCLEXTA for the treatment of patients with CLL who have received at least one prior therapy and who have failed a BCRi #MarketAccess (Canada)

Zorginstituut removes Fampyra from its basic insurance package after having been conditionally approved for reimbursement in April 2016 for 2 years #MarketAccess (Netherlands)